The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

demonstrated that daratumumab, a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells, significantly reduces the risk of progression to active multiple myeloma ...

demonstrated that daratumumab, a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells, significantly reduces the risk of progression to active multiple myeloma ...

It joins a number of other BCMA-directed therapies for multiple myeloma ... generated anti-CD38 blockbuster Darzalex (daratumumab). Talquetamab has also shown promise in myeloma in the phase ...

Another anti-CD38 monoclonal antibody, daratumumab (Darzalex ... and dexamethasone for patients newly diagnosed with multiple myeloma. In the IRAKLIA study, investigators used an OBDS developed ...

The FDA approved daratumumab-hyaluronidase injection for adult patients with newly diagnosed or relapsed/refractory multiple myeloma in May 2020, and it is now approved for nine indications in ...

GSK continues to build the case for its multiple myeloma therapy Blenrep ... Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM ...

The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.

Previously we used to use Anti-CD38 ... myeloma also include the use of PCMA based therapy. BCMA is B-cell maturation antigen and it is a way for us to target the myeloma cell. So there are ...

Daratumumab, hyaluronidase-fihj ... a polysaccharide found in the extracellular matrix. Treatment of multiple myeloma: in combination with bortezomib, lenalidomide, and dexamethasone for induction ...